Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8499855 | 0.95 | LMNA (0.43) | SMN1; SMN2PTPN1LMNAALDH1A1HSD17B10 | |
| SCHEMBL27089875 | 0.95 | LMNA (0.43) | SMN1; SMN2PTPN1LMNAALDH1A1HSD17B10 | |
| SCHEMBL19385898 | 0.95 | LMNA (0.35) | SMN1; SMN2PTPN1LMNAALDH1A1HSD17B10 | |
| SCHEMBL12865774 | 0.93 | LMNA (0.38) | PTPN1LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL22391537 | 0.93 | LMNA (0.38) | PTPN1LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL22391538 | 0.93 | LMNA (0.38) | PTPN1LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL28884337 | 0.92 | LMNA (0.39) | SMN1; SMN2PTPN1LMNAALDH1A1HSD17B10 | |
| SCHEMBL29108482 | 0.90 | SMN1; SMN2 (0.32) | SMN1; SMN2LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL14834118 | 0.89 | CA2 (0.36) | LMNATSHRCA2 | |
| SCHEMBL18022040 | 0.87 | CA2 (0.35) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058305-B2 | Pyrrolidine derivatives as prostaglandin modulators | MERCK SERONO SA (CH) | 2011-11-15 | — | — | US | disclosed |
| EP-1458679-B1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | MERCK SERONO SA (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-7635713-B2 | Pyrrolidine derivatives as prostaglandin modulators | LABORATOIRES SERONO SA (CH) | 2009-12-22 | — | — | US | disclosed |
| US-20090292000-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2009-11-26 | — | — | US | disclosed |
| US-20080114051-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2008-05-15 | — | — | US | disclosed |
| US-7335680-B2 | Pyrrolidine derivatives as prostaglandin modulators | LABORATOIRES SERONO SA (CH) | 2008-02-26 | — | — | US | disclosed |
| US-20050176800-A1 | Pyrrolidine derivatives as prostaglandin modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-08-11 | — | — | US | disclosed |
| EP-1458679-A2 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003053923-A2 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292000-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | PGF, PTGIS, PDE5A | SMN1; SMN2 1678/4885PTPN1 2971/4885LMNA 2337/4885 |
| US-20050176800-A1 | Pyrrolidine derivatives as prostaglandin modulators | PGF, PTGIS, PTGIR | SMN1; SMN2 2696/4885PTPN1 2963/4885LMNA 2636/4885 |
| US-20080114051-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | PGF, PTGIS, PDE5A | SMN1; SMN2 1678/4885PTPN1 2971/4885LMNA 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.